Glenn Hubbard: Why the case for more Fed cuts is so hard to make #shorts #fed #ratecuts #powellDecember 14, 2025
Share Facebook Twitter LinkedIn Pinterest Email Carter Worth, Worth Charting, joins Fast Money with the technicals on the pharma sector, bullish reversal patterns in Merck, Biogen, and Pfizer, why bombed-out names may offer more upside than Johnson & Johnson, and more.